Annual Total Expenses
$772.02 M
+$126.75 M+19.64%
December 31, 2022
Summary
- As of February 11, 2025, MRTX annual total expenses is $772.02 million, with the most recent change of +$126.75 million (+19.64%) on December 31, 2022.
- During the last 3 years, MRTX annual total expenses has risen by +$546.59 million (+242.45%).
Performance
MRTX Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Total Expenses
$188.45 M
-$12.51 M-6.22%
September 30, 2023
Summary
- As of February 11, 2025, MRTX quarterly total expenses is $188.45 million, with the most recent change of -$12.51 million (-6.22%) on September 30, 2023.
- Over the past year, MRTX quarterly total expenses has dropped by -$3.42 million (-1.78%).
Performance
MRTX Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Total Expenses Formula
Total Expenses = Cost of Goods Sold + Operating Expenses + Non Operating Expenses
MRTX Total Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +19.6% | -1.8% |
| 3 y3 years | +242.4% | +88.3% |
| 5 y5 years | +979.2% | +551.2% |
MRTX Total Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | -16.4% | -11.4% | -3.1% |
| 5 y | 5-year | at high | -70.8% | -11.4% | -60.1% |
| alltime | all time | at high | -98.5% | -11.4% | -99.8% |
Mirati Therapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2023 | - | $188.45 M(-6.2%) |
| Jun 2023 | - | $200.96 M(-0.0%) |
| Mar 2023 | - | $200.99 M(-5.5%) |
| Dec 2022 | $772.02 M(+19.6%) | $212.66 M(+10.8%) |
| Sep 2022 | - | $191.87 M(+5.1%) |
| Jun 2022 | - | $182.57 M(-1.3%) |
| Mar 2022 | - | $184.93 M(-6.3%) |
| Dec 2021 | $645.27 M(+68.6%) | $197.37 M(+30.5%) |
| Sep 2021 | - | $151.29 M(-7.9%) |
| Jun 2021 | - | $164.19 M(+24.0%) |
| Mar 2021 | - | $132.42 M(+22.6%) |
| Dec 2020 | $382.76 M(+69.8%) | $108.04 M(+7.9%) |
| Sep 2020 | - | $100.10 M(+18.0%) |
| Jun 2020 | - | $84.86 M(-5.5%) |
| Mar 2020 | - | $89.75 M(+19.4%) |
| Dec 2019 | $225.44 M(+95.1%) | $75.17 M(+29.5%) |
| Sep 2019 | - | $58.05 M(+20.4%) |
| Jun 2019 | - | $48.22 M(+9.6%) |
| Mar 2019 | - | $44.00 M(+32.8%) |
| Dec 2018 | $115.55 M(+61.5%) | $33.13 M(+14.5%) |
| Sep 2018 | - | $28.94 M(+0.9%) |
| Jun 2018 | - | $28.67 M(+15.5%) |
| Mar 2018 | - | $24.81 M(+36.1%) |
| Dec 2017 | $71.53 M(-14.6%) | $18.23 M(+9.8%) |
| Sep 2017 | - | $16.60 M(-10.8%) |
| Jun 2017 | - | $18.62 M(+2.9%) |
| Mar 2017 | - | $18.09 M(-8.9%) |
| Dec 2016 | $83.78 M(+29.5%) | $19.85 M(+1.4%) |
| Sep 2016 | - | $19.58 M(-11.9%) |
| Jun 2016 | - | $22.23 M(+0.5%) |
| Mar 2016 | - | $22.12 M(+19.6%) |
| Dec 2015 | $64.71 M(+66.9%) | $18.49 M(-1.3%) |
| Sep 2015 | - | $18.72 M(+20.7%) |
| Jun 2015 | - | $15.52 M(+29.5%) |
| Mar 2015 | - | $11.99 M(+14.8%) |
| Dec 2014 | $38.77 M | $10.44 M(-1.0%) |
| Sep 2014 | - | $10.55 M(+4.1%) |
| Jun 2014 | - | $10.13 M(+32.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $7.64 M(+11.4%) |
| Dec 2013 | $30.97 M(+51.1%) | $6.86 M(-25.5%) |
| Sep 2013 | - | $9.21 M(+33.6%) |
| Jun 2013 | - | $6.89 M(-13.8%) |
| Mar 2013 | - | $8.00 M(+25.5%) |
| Dec 2012 | $20.50 M(+59.5%) | $6.37 M(+6.8%) |
| Sep 2012 | - | $5.97 M(+26.0%) |
| Jun 2012 | - | $4.73 M(+38.3%) |
| Mar 2012 | - | $3.42 M(-18.5%) |
| Dec 2011 | $12.85 M(-24.7%) | $4.20 M(+33.4%) |
| Sep 2011 | - | $3.15 M(+6.8%) |
| Jun 2011 | - | $2.95 M(+0.6%) |
| Mar 2011 | - | $2.93 M(-10.4%) |
| Dec 2010 | $17.06 M(-32.9%) | $3.27 M(-36.7%) |
| Sep 2010 | - | $5.17 M(+37.1%) |
| Jun 2010 | - | $3.77 M(-21.8%) |
| Mar 2010 | - | $4.82 M(-16.9%) |
| Dec 2009 | $25.45 M(-22.9%) | $5.81 M(+6.0%) |
| Sep 2009 | - | $5.48 M(-1.7%) |
| Jun 2009 | - | $5.58 M(-9.8%) |
| Mar 2009 | - | $6.18 M(+124.0%) |
| Dec 2008 | $33.02 M(-19.4%) | $2.76 M(-70.5%) |
| Sep 2008 | - | $9.34 M(-20.3%) |
| Jun 2008 | - | $11.73 M(+18.2%) |
| Mar 2008 | - | $9.92 M(-27.6%) |
| Dec 2007 | $40.96 M(+141.2%) | $13.70 M(+39.8%) |
| Sep 2007 | - | $9.80 M(+6.8%) |
| Jun 2007 | - | $9.18 M(+40.1%) |
| Mar 2007 | - | $6.55 M(+2089.2%) |
| Dec 2006 | $16.98 M(-11.2%) | $299.30 K(-94.6%) |
| Sep 2006 | - | $5.54 M(-2.4%) |
| Jun 2006 | - | $5.67 M(+8.0%) |
| Mar 2006 | - | $5.25 M(-1.0%) |
| Dec 2005 | $19.12 M(+18.1%) | $5.30 M(+13.1%) |
| Sep 2005 | - | $4.69 M(+1.8%) |
| Jun 2005 | - | $4.60 M(+12.0%) |
| Mar 2005 | - | $4.11 M |
| Dec 2004 | $16.19 M(+36.8%) | - |
| Dec 2003 | $11.83 M | - |
FAQ
- What is Mirati Therapeutics annual total expenses?
- What is the all time high annual total expenses for Mirati Therapeutics?
- What is Mirati Therapeutics annual total expenses year-on-year change?
- What is Mirati Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Mirati Therapeutics?
- What is Mirati Therapeutics quarterly total expenses year-on-year change?
What is Mirati Therapeutics annual total expenses?
The current annual total expenses of MRTX is $772.02 M
What is the all time high annual total expenses for Mirati Therapeutics?
Mirati Therapeutics all-time high annual total expenses is $772.02 M
What is Mirati Therapeutics annual total expenses year-on-year change?
Over the past year, MRTX annual total expenses has changed by +$126.75 M (+19.64%)
What is Mirati Therapeutics quarterly total expenses?
The current quarterly total expenses of MRTX is $188.45 M
What is the all time high quarterly total expenses for Mirati Therapeutics?
Mirati Therapeutics all-time high quarterly total expenses is $212.66 M
What is Mirati Therapeutics quarterly total expenses year-on-year change?
Over the past year, MRTX quarterly total expenses has changed by -$3.42 M (-1.78%)